Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1997 Feb;6(1):32–38. doi: 10.1080/09629359791901

Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumour necrosis factor

M Romano 1,✉, R Faggioni 1, M Sironi 1, S Sacco 1, B Echtenacher 2, E Di Santo 1, M Salmona 1, P Ghezzi 1
PMCID: PMC2365839  PMID: 18472831

Abstract

We used the mouse air pouch model of inflammation to study the interaction between cytokines, prostaglandin E2 (PGE2) and cell migration during the various phases of acute local inflammation induced by carrageenan. In serum, the levels of interleukin 1 (IL-1), interleukin 6 (IL-6), tumour necrosis factor (TNF), serum amiloid-A (SAA) and Fe++ were never different from controls, indicating that no systemic inflammatory changes were induced. Locally the exudate volume and the number of leukocytes recruited into the pouch increased progressively until 7 days after carrageenan. The same was true for PGE2 production. We could not measure IL-1 but the production of IL-6 and TNF reached a maximum after 5-24 h then quickly decreased. Anti-TNF antibodies inhibited cell migration by 50% 24 h after treatment. Pretreatment with interleukin 10 (IL-10) inhibited TNF production almost completely and cell migration by 60%. Carrageenan-induced inflammation was modulated by anti-inflammatory drugs. Pretreatment with dexamethasone (DEX) or indomethacin (INDO) inhibited cell migration and reduced the concentration of TNF in the exudate. Production of PGE2 or vascular permeability did not correlate with the number of cells in the pouch. Local TNF seems to play an important role in this model, particularly for leukocyte migration in the first phase of the inflammatory process. In conclusion, the air pouch seems to be a good model for studying the regulation of the early events of local inflammation, particularly the role of cytokines and cell migration.

Full Text

The Full Text of this article is available as a PDF (289.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beutler B., Milsark I. W., Cerami A. C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. doi: 10.1126/science.3895437. [DOI] [PubMed] [Google Scholar]
  2. Brennan F. M., Chantry D., Jackson A., Maini R., Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989 Jul 29;2(8657):244–247. doi: 10.1016/s0140-6736(89)90430-3. [DOI] [PubMed] [Google Scholar]
  3. Edwards J. C., Sedgwick A. D., Willoughby D. A. The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J Pathol. 1981 Jun;134(2):147–156. doi: 10.1002/path.1711340205. [DOI] [PubMed] [Google Scholar]
  4. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  5. Fattori E., Cappelletti M., Costa P., Sellitto C., Cantoni L., Carelli M., Faggioni R., Fantuzzi G., Ghezzi P., Poli V. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med. 1994 Oct 1;180(4):1243–1250. doi: 10.1084/jem.180.4.1243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gadina M., Bertini R., Mengozzi M., Zandalasini M., Mantovani A., Ghezzi P. Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock. J Exp Med. 1991 Jun 1;173(6):1305–1310. doi: 10.1084/jem.173.6.1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gérard C., Bruyns C., Marchant A., Abramowicz D., Vandenabeele P., Delvaux A., Fiers W., Goldman M., Velu T. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med. 1993 Feb 1;177(2):547–550. doi: 10.1084/jem.177.2.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hopkins S. J., Meager A. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Clin Exp Immunol. 1988 Jul;73(1):88–92. [PMC free article] [PubMed] [Google Scholar]
  9. Howard M., Muchamuel T., Andrade S., Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med. 1993 Apr 1;177(4):1205–1208. doi: 10.1084/jem.177.4.1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Husby G., Williams R. C., Jr Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun. 1988 Aug;1(4):363–371. doi: 10.1016/0896-8411(88)90006-6. [DOI] [PubMed] [Google Scholar]
  11. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., Kollias G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991 Dec;10(13):4025–4031. doi: 10.1002/j.1460-2075.1991.tb04978.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kunkel S. L., Chensue S. W. Arachidonic acid metabolites regulate interleukin-1 production. Biochem Biophys Res Commun. 1985 Apr 30;128(2):892–897. doi: 10.1016/0006-291x(85)90130-5. [DOI] [PubMed] [Google Scholar]
  13. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci. 1982;389:39–48. doi: 10.1111/j.1749-6632.1982.tb22124.x. [DOI] [PubMed] [Google Scholar]
  14. Pettipher E. R., Wimberly D. J. Cyclooxygenase inhibitors enhance tumour necrosis factor production and mortality in murine endotoxic shock. Cytokine. 1994 Sep;6(5):500–503. doi: 10.1016/1043-4666(94)90077-9. [DOI] [PubMed] [Google Scholar]
  15. Remick D. G. Significance of in vivo detection of tumor necrosis factor. Lab Invest. 1991 Sep;65(3):259–261. [PubMed] [Google Scholar]
  16. Renz H., Gong J. H., Schmidt A., Nain M., Gemsa D. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol. 1988 Oct 1;141(7):2388–2393. [PubMed] [Google Scholar]
  17. Sedgwick A. D., Lees P. Studies of eicosanoid production in the air pouch model of synovial inflammation. Agents Actions. 1986 Jun;18(3-4):429–438. doi: 10.1007/BF01965008. [DOI] [PubMed] [Google Scholar]
  18. Sedgwick A. D., Sin Y. M., Edwards J. C., Willoughby D. A. Increased inflammatory reactivity in newly formed lining tissue. J Pathol. 1983 Dec;141(4):483–495. doi: 10.1002/path.1711410406. [DOI] [PubMed] [Google Scholar]
  19. Sekut L., Menius J. A., Jr, Brackeen M. F., Connolly K. M. Evaluation of the significance of elevated levels of systemic and localized tumor necrosis factor in different animal models of inflammation. J Lab Clin Med. 1994 Dec;124(6):813–820. [PubMed] [Google Scholar]
  20. Simmons P. M., Salmon J. A., Moncada S. The release of leukotriene B4 during experimental inflammation. Biochem Pharmacol. 1983 Apr 15;32(8):1353–1359. doi: 10.1016/0006-2952(83)90446-x. [DOI] [PubMed] [Google Scholar]
  21. Sin Y. M., Sedgwick A. D., Chea E. P., Willoughby D. A. Mast cells in newly formed lining tissue during acute inflammation: a six day air pouch model in the mouse. Ann Rheum Dis. 1986 Oct;45(10):873–877. doi: 10.1136/ard.45.10.873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sin Y. M., Tan C. H., Chan S. F. Changes in histamine and prostaglandins in acute inflammatory air pouch in mice. Agents Actions. 1989 Aug;28(1-2):98–102. doi: 10.1007/BF02022988. [DOI] [PubMed] [Google Scholar]
  23. Sipe J. D., Gonnerman W. A., Loose L. D., Knapschaefer G., Xie W. J., Franzblau C. Direct binding enzyme-linked immunosorbent assay (ELISA) for serum amyloid A (SAA). J Immunol Methods. 1989 Dec 20;125(1-2):125–135. doi: 10.1016/0022-1759(89)90085-9. [DOI] [PubMed] [Google Scholar]
  24. Smith-Oliver T., Noel L. S., Stimpson S. S., Yarnall D. P., Connolly K. M. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine. 1993 Jul;5(4):298–304. doi: 10.1016/1043-4666(93)90060-i. [DOI] [PubMed] [Google Scholar]
  25. Spengler R. N., Spengler M. L., Strieter R. M., Remick D. G., Larrick J. W., Kunkel S. L. Modulation of tumor necrosis factor-alpha gene expression. Desensitization of prostaglandin E2-induced suppression. J Immunol. 1989 Jun 15;142(12):4346–4350. [PubMed] [Google Scholar]
  26. Strieter R. M., Kunkel S. L., Bone R. C. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med. 1993 Oct;21(10 Suppl):S447–S463. doi: 10.1097/00003246-199310001-00006. [DOI] [PubMed] [Google Scholar]
  27. Watanabe S., Kobayashi T., Okuyama H. Regulation of lipopolysaccharide-induced tumor necrosis factor alpha production by endogenous prostaglandin E2 in rat resident and thioglycollate-elicited macrophages. J Lipid Mediat Cell Signal. 1994 Sep;10(3):283–294. [PubMed] [Google Scholar]
  28. Zhang Y., Ramos B. F., Jakschik B. A. Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. Science. 1992 Dec 18;258(5090):1957–1959. doi: 10.1126/science.1470922. [DOI] [PubMed] [Google Scholar]
  29. da Motta J. I., Cunha F. Q., Vargaftig B. B., Ferreira S. H. Drug modulation of antigen-induced paw oedema in guinea-pigs: effects of lipopolysaccharide, tumour necrosis factor and leucocyte depletion. Br J Pharmacol. 1994 May;112(1):111–116. doi: 10.1111/j.1476-5381.1994.tb13038.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES